• Alembic Pharmaceutical’s consolidated revenues for the quarter ended December (Q3FY22) were down 2% quarter-on-quarter (QoQ). On a year-on-year (YoY) basis, it witnessed a decline of 3%.
  • Its expenses for the quarter were down 2% QoQ and up 8% YoY.
  • While the company reported a 3% QoQ net profit growth, the same fell by 41% on a YoY basis.
  • The earnings per share (EPS) of Alembic Pharmaceutical’ stood at 9 during Q3FY22.

Alembic Pharmaceutical’s Financial Statements for Q3FY22:

(Rs, crores) Q3FY21 Q2FY22 Q3FY22 QoQ (%) YoY (%)
Total Income 1,317 1,295 1,273 -2% -3%
Total Expenses 999 1,094 1,076 -2% 8%
Profit before tax 318 200 197 -2% -38%
Tax 59 40 32 -18% -45%
Profit after tax 286 164 168 3% -41%
Earnings per share 14.9 8.6 9.0    

Data Source: BSE, Company announcements

Want to get more analysis on Indian listed companies? Open an account and get daily stock research updates from Kotak Securities.

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results